Spots Global Cancer Trial Database for vectibix
Every month we try and update this database with for vectibix cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Observational Study of Vectibix With Chemotherapy for Metastatic Colorectal Cancer Patients | NCT01732783 | Wild-type RAS M... | Panitumumab + C... | 18 Years - | Amgen | |
| New Individualized Therapy Trial for Metastatic Colorectal Cancer | NCT00867334 | Colorectal Neop... Colorectal Canc... | Imatinib mesyla... Standard-of-car... | 18 Years - | Inova Health Care Services | |
| CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater | NCT01202409 | Gastrointestina... | Panitumumab | 18 Years - | M.D. Anderson Cancer Center | |
| Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer | NCT00894504 | Metastatic Brea... | Panitumumab Carboplatin Gemcitabine | 18 Years - | SCRI Development Innovations, LLC | |
| PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors | NCT00819780 | Colon Cancer Colorectal Canc... Rectal Cancer Metastatic Colo... | Panitumumab Bevacizumab mFOLFOX6 | 18 Years - | Amgen | |
| Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLC | NCT01042288 | Non-Small-Cell ... | Carboplatin Pemetrexed Panitumumab | 18 Years - | SCRI Development Innovations, LLC | |
| Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer | NCT00894504 | Metastatic Brea... | Panitumumab Carboplatin Gemcitabine | 18 Years - | SCRI Development Innovations, LLC | |
| Selective IMRT for Locally Advanced Head and Neck Carcinoma With Concurrent Panitumumab | NCT01312493 | Head and Neck C... | Panitumumab Intensity Modul... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC) | NCT00788957 | Colon Cancer Colorectal Canc... Gastrointestina... Metastatic Colo... Rectal Cancer | Panitumumab Ganitumab Rilotumumab Placebo | 18 Years - | Amgen | |
| Safety, Tolerability and Efficacy Study of Doxycycline Foam for the Prevention of EGFRI Skin Toxicity in Cancer Patients | NCT02239731 | Rash Due to Epi... | FDX104 (4% Doxy... | 18 Years - | Vyne Therapeutics Inc. | |
| Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer | NCT00894504 | Metastatic Brea... | Panitumumab Carboplatin Gemcitabine | 18 Years - | SCRI Development Innovations, LLC | |
| Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer | NCT00089635 | Colorectal Canc... Metastases | Panitumumab | 18 Years - | Amgen | |
| Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer | NCT00089635 | Colorectal Canc... Metastases | Panitumumab | 18 Years - | Amgen | |
| Assessment of the Efficacy of the Neoadjuvant Combination: "Chemotherapy-Targeted Therapy" in Breast Cancer. | NCT00933517 | Pathological Re... | vectibix fluorouracile Epirubicine cyclophosphamid... docetaxel | 18 Years - | Centre Jean Perrin | |
| New Individualized Therapy Trial for Metastatic Colorectal Cancer | NCT00867334 | Colorectal Neop... Colorectal Canc... | Imatinib mesyla... Standard-of-car... | 18 Years - | Inova Health Care Services | |
| Panitumumab and Irinotecan for Malignant Gliomas | NCT01017653 | Malignant Gliom... | Irinotecan Panitumumab | 18 Years - | Duke University | |
| PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors | NCT00819780 | Colon Cancer Colorectal Canc... Rectal Cancer Metastatic Colo... | Panitumumab Bevacizumab mFOLFOX6 | 18 Years - | Amgen | |
| PiCCA Study (Panitumumab in Combination With Cisplatin/Gemcitabine) | NCT01320254 | Cholangiocarcin... | Cisplatin, Gemc... Cisplatin, Gemc... | 18 Years - | Hannover Medical School | |
| Evaluating Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy | NCT00083616 | Colorectal Canc... Metastatic Canc... | Panitumumab | 18 Years - | Amgen | |
| Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer | NCT00894504 | Metastatic Brea... | Panitumumab Carboplatin Gemcitabine | 18 Years - | SCRI Development Innovations, LLC | |
| Assessment of the Efficacy of the Neoadjuvant Combination: "Chemotherapy-Targeted Therapy" in Breast Cancer. | NCT00933517 | Pathological Re... | vectibix fluorouracile Epirubicine cyclophosphamid... docetaxel | 18 Years - | Centre Jean Perrin | |
| ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer | NCT01001377 | Metastatic Colo... | Cetuximab Panitumumab | 18 Years - | Amgen | |
| Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer | NCT01036087 | Breast Cancer | Panitumumab Nab-paclitaxel Carboplatin 5-Fluorouracil Epirubicin Cyclophosphamid... | 18 Years - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
